The effect of Hurricane Beryl on Houston's Johnson Space Center, home to the control centers for both NASA and Boeing, also contributed to the delay for NASA test pilots Butch Wilmore and Suni Williams. Photo via Boeing

Two astronauts who should have been back on Earth weeks ago said Wednesday that they’re confident that Boeing’s space capsule can return them safely, despite a string of vexing breakdowns.

NASA test pilots Butch Wilmore and Suni Williams launched aboard Boeing’s new Starliner capsule early last month, the first people to ride it. Helium leaks and thruster failures almost derailed their arrival at the International Space Station, and have kept them there much longer than planned. Now the earliest they could return may be the end of July, officials said.

In their first news conference from orbit, the pair said they expect to return once thruster testing is complete here on Earth. They said they’re not complaining about getting extra time in orbit, and are enjoying helping the station crew. Both have previously spent stints at the orbiting lab, which is also home to seven others.

“I have a real good feeling in my heart that the spacecraft will bring us home, no problem," Williams told reporters.

The test flight should have lasted eight days, ending on June 14.

NASA's commercial crew program director Steve Stich said the earliest the Starliner astronauts might return is the end of July. The goal is to get them back before SpaceX delivers a fresh crew in mid-August, but that, too, could change, he noted.

Hurricane Beryl slowed some of the work. Johnson Space Center in Houston, home to the control centers for both NASA and Boeing, was closed earlier this week to all but the most critical staff.

This week, NASA and Boeing are trying to duplicate the Starliner's thruster problems on a brand new unit at White Sands Missile Range in New Mexico, one of the prime landing sites in the U.S. western desert. The trouble is in the propulsion system, used to maneuver the spacecraft.

Five thrusters failed as the capsule approached the space station on June 6, a day after liftoff. Four have since been reactivated. Wilmore said there should be enough working thrusters to get him and Williams out of orbit. There are also bigger engines that could fill in, if necessary.

“That mantra you’ve heard, failure is not an option, that’s why we are staying here now," Wilmore said. “We trust that the tests that we’re doing are the ones we need to do to get the right answers, to give us the data that we need to come back.”

Boeing and NASA consider the ground tests essential to determine what might have gone wrong since that part of the capsule — the service module — is discarded before landing. The leaks also are located in this disposable section.

So far, testing has not replicated the hot temperatures reached during the flight, according to Stich. Managers want to make sure the suspect thrusters are not damaged, before bringing Starliner back. They were fired more frequently than anticipated early in the flight, and the extra demand on them may have caused them to fail, Stich noted.

At the same time, ground tests are being conducted to better understand the helium leaks, which could stem from bad seals. Officials have previously said there is ample helium left for the trip home.

Boeing's Mark Nappi stressed that in an emergency, Starliner and its crew could return right now. While the company does not believe the thrusters are damaged, "we want to fill in the blanks and run this test to assure ourselves of that."

NASA ordered up the Starliner and SpaceX Dragon capsules a decade ago for astronaut flights to and from the space station, paying each company billions of dollars. SpaceX's first taxi flight with astronauts was in 2020. Boeing's first crew flight was repeatedly delayed because of software and other issues.

There have been no discussions with SpaceX about sending up a rescue capsule, Stich said.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."